Medicaid Urges States to Increase Autism Therapy Oversight

Meticulously balanced checkbooks do not guarantee a healthy child. When Medicaid’s autism therapy spending quintuples while the diagnosis rate merely inches upward, we are no longer looking at a health trend—we are looking at a systemic aberration. We often accept that "more care" is synonymous with "better care." But this data exposes a more sinister economic gravity well: where billions of dollars flow, predatory actors follow. This isn't about denying legitimacy to children who need applied behavior analysis; it is about identifying the pressure points where clinical necessity bends to billing quotas. If we tolerate a system where the only symptom is the invoice, we betray the very families we sought to protect. The signal here is the commodification of neurodivergence. Washington's push for oversight is a vital first step, but they must go further—demanding granular outcome data, not just audit trails. In that gap between the diagnostic spike and the billing bonanza lies the true pathology of our healthcare system. We cannot let the greed of a few foreclose the compassion we owe to the many. Therapy must never be a line item. It’s a lifeline. ```json { "key_insight": "The divergence between diagnosis rates and therapy spending suggests a failure of clinical gatekeeping, where financial incentives have outpaced medical need, risking care quality for vulnerable children.", "confidence": 0 } ```